156 related articles for article (PubMed ID: 17377809)
1. Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer.
Woenckhaus J; Steger K; Sturm K; Münstedt K; Franke FE; Fenic I
Virchows Arch; 2007 Apr; 450(4):387-95. PubMed ID: 17377809
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.
Abe A; Minaguchi T; Ochi H; Onuki M; Okada S; Matsumoto K; Satoh T; Oki A; Yoshikawa H
Hum Pathol; 2013 Feb; 44(2):199-207. PubMed ID: 22955107
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.
Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT
Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA alterations in Middle Eastern ovarian cancers.
Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
6. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
8. Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Fenic I; Steger K; Gruber C; Arens C; Woenckhaus J
Oncol Rep; 2007 Jul; 18(1):253-9. PubMed ID: 17549376
[TBL] [Abstract][Full Text] [Related]
9. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
Redon R; Muller D; Caulee K; Wanherdrick K; Abecassis J; du Manoir S
Cancer Res; 2001 May; 61(10):4122-9. PubMed ID: 11358835
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.
Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Ellis IO; Green AR
Breast Cancer Res Treat; 2011 Jun; 127(2):407-16. PubMed ID: 20617378
[TBL] [Abstract][Full Text] [Related]
11. The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
Zhang L; Yang N; Katsaros D; Huang W; Park JW; Fracchioli S; Vezzani C; Rigault de la Longrais IA; Yao W; Rubin SC; Coukos G
Cancer Res; 2003 Jul; 63(14):4225-31. PubMed ID: 12874030
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Shigaki H; Baba Y; Watanabe M; Murata A; Ishimoto T; Iwatsuki M; Iwagami S; Nosho K; Baba H
Clin Cancer Res; 2013 May; 19(9):2451-9. PubMed ID: 23532889
[TBL] [Abstract][Full Text] [Related]
13. Increased Expression of Phosphatidylinositol 3-Kinase p110α and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma.
Yip WK; He PY; Abdullah MA; Yusoff S; Seow HF
Pathol Oncol Res; 2016 Apr; 22(2):413-9. PubMed ID: 26581613
[TBL] [Abstract][Full Text] [Related]
14. Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.
De Marco C; Rinaldo N; Bruni P; Malzoni C; Zullo F; Fabiani F; Losito S; Scrima M; Marino FZ; Franco R; Quintiero A; Agosti V; Viglietto G
PLoS One; 2013; 8(2):e55362. PubMed ID: 23408974
[TBL] [Abstract][Full Text] [Related]
15. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.
Noske A; Kaszubiak A; Weichert W; Sers C; Niesporek S; Koch I; Schaefer B; Sehouli J; Dietel M; Lage H; Denkert C
Cancer Lett; 2007 Feb; 246(1-2):190-200. PubMed ID: 16584837
[TBL] [Abstract][Full Text] [Related]
16. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.
Massion PP; Taflan PM; Shyr Y; Rahman SM; Yildiz P; Shakthour B; Edgerton ME; Ninan M; Andersen JJ; Gonzalez AL
Am J Respir Crit Care Med; 2004 Nov; 170(10):1088-94. PubMed ID: 15317667
[TBL] [Abstract][Full Text] [Related]
17. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.
Shi J; Yao D; Liu W; Wang N; Lv H; Zhang G; Ji M; Xu L; He N; Shi B; Hou P
BMC Cancer; 2012 Feb; 12():50. PubMed ID: 22292935
[TBL] [Abstract][Full Text] [Related]
18. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer.
Hua K; Feng W; Cao Q; Zhou X; Lu X; Feng Y
Int J Oncol; 2008 Nov; 33(5):959-67. PubMed ID: 18949358
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA is implicated as an oncogene in ovarian cancer.
Shayesteh L; Lu Y; Kuo WL; Baldocchi R; Godfrey T; Collins C; Pinkel D; Powell B; Mills GB; Gray JW
Nat Genet; 1999 Jan; 21(1):99-102. PubMed ID: 9916799
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation.
Bertelsen BI; Steine SJ; Sandvei R; Molven A; Laerum OD
Int J Cancer; 2006 Apr; 118(8):1877-83. PubMed ID: 16287065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
